Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT04009681
Previous Study | Return to List | Next Study

A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors (THOR-707-101)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04009681
Recruitment Status : Recruiting
First Posted : July 5, 2019
Last Update Posted : July 11, 2022
Sponsor:
Information provided by (Responsible Party):
Synthorx, Inc, a Sanofi company

Brief Summary:

Primary Objectives:

  • Evaluate the safety and tolerability of THOR-707 as a single agent and as a combination therapy (identify Dose Limiting Toxcitiy (DLTs), Adverse Events (AEs)/serious adverse event (SAE) profile)
  • Define the Maximum Tolerated Dose (MTD) and/or the Recommended Phase 2 Dose (RP2D) of THOR-707 as a single agent and as a combination therapy

Secondary Objectives:

  • Evaluate preliminary anti-tumor activity of THOR-707 as a single agent and as a combination therapy by determination of the objective response rate (ORR) defined according to the Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1
  • Determine time to response (TTR), duration of response (DOR), progression-free survival (PFS), overall survival (OS), and disease control rate (DCR) of THOR-707 as a single agent and as a combination therapy

Condition or disease Intervention/treatment Phase
Metastasis Drug: THOR-707 Drug: Checkpoint inhibitor Drug: anti-EGFR antibody Phase 1 Phase 2

Detailed Description:
The study duration per participant is approximately 24 months (inclusive of follow-up).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 300 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors
Actual Study Start Date : June 20, 2019
Estimated Primary Completion Date : August 14, 2023
Estimated Study Completion Date : August 14, 2023

Arm Intervention/treatment
Experimental: Cohort A-THOR-707 Monotherapy and Dose Escalation Q2W
Dose Escalation: THOR-707 will be administered in sequential ascending doses as a monotherapy via intravenous (IV) administration every 2 weeks (Q2W) until unacceptable toxicity, disease progression, or withdrawal of consent.
Drug: THOR-707
Pharmaceutical form: solution for intravenous (IV) administration Route of administration: IV administration
Other Name: SAR444245

Experimental: Cohort B-THOR-707 Monotherapy and Dose Escalation Q3W
Dose Escalation: THOR-707 will be administered in sequential ascending doses as a monotherapy via IV administration every 3 weeks (Q3W) until unacceptable toxicity, disease progression, or withdrawal of consent.
Drug: THOR-707
Pharmaceutical form: solution for intravenous (IV) administration Route of administration: IV administration
Other Name: SAR444245

Experimental: Cohort C-THOR-707 with checkpoint inhibitor and dose escalation
Dose Escalation: TTHOR-707 will be administered in sequential ascending doses in combination with a checkpoint inhibitor via IV administration Q3W or every 6 weeks (Q6W) until unacceptable toxicity, disease progression, or withdrawal of consent.
Drug: THOR-707
Pharmaceutical form: solution for intravenous (IV) administration Route of administration: IV administration
Other Name: SAR444245

Drug: Checkpoint inhibitor
Pharmaceutical form: solution for intravenous (IV) administration Route of administration: IV administration

Experimental: Cohort D-THOR-707 with anti-EGFR antibody and dose escalation
Dose Escalation: THOR-707 will be administered in sequential ascending doses in combination with an anti-EGFR antibody via IV administration Q3W/QW (once-weekly) (respectively) until unacceptable toxicity, disease progression, or withdrawal of consent.
Drug: THOR-707
Pharmaceutical form: solution for intravenous (IV) administration Route of administration: IV administration
Other Name: SAR444245

Drug: anti-EGFR antibody
Pharmaceutical form: solution for intravenous (IV) administration Route of administration: IV administration




Primary Outcome Measures :
  1. Rate of Dose-Limiting Toxicities (DLTs) [ Time Frame: Study Day 1 up to Day 29 ]
    Based on toxicities observed

  2. Maximum Tolerated Dose (MTD) [ Time Frame: Study Day 1 up to Day 29 ]
    Based on toxicities observed

  3. Recommended Phase 2 Dose (RP2D) [ Time Frame: Study Day 1 up to Day 29 ]
    Based on toxicities observed


Secondary Outcome Measures :
  1. Objective Response Rate (ORR) according to RECIST version 1.1 [ Time Frame: Study Day 1, assessed up to 24 months ]
    Defined as the proportion of subjects with confirmed complete response (CR) or partial response (PR); a confirmed response is a response that persists on repeat-imaging ≥4 weeks after initial documentation of response.

  2. Duration of Response (DOR) according to RECIST version 1.1 [ Time Frame: Study Day 1, assessed up to 24 months ]
    Defined as time from date of first objective response (either CR or PR) to first documentation of radiographic disease progression or death due to any cause, whichever occurs first.

  3. Progression-Free Survival (PFS) according to RECIST version 1.1 [ Time Frame: Study Day 1 until the date of first documented progression or date of death from any cause, assessed up to 24 months ]
    Defined as the time from first dose of THOR-707 to first documentation of radiographic disease progression or death due to any cause, whichever occurs first.

  4. Overall Survival according to RECIST version 1.1 [ Time Frame: Study Day 1 up to time of death, assessed up to 24 months ]
    Defined as the time from first dose of THOR-707 to the date of death due to any cause.

  5. Time to Response (TTR) according to RECIST version 1.1 [ Time Frame: Study Day 1, assessed up to 24 months ]
    Defined as the time from first dose of THOR-707 to first documentation of objective response (either CR or PR).

  6. Disease Control Rate (DCR) according to RECIST version 1.1 [ Time Frame: Study Day 1, assessed up to 24 months ]
    Defined as the proportion of subjects who have achieved CR, PR, or stable disease (duration of stable disease should be ≥3 months).

  7. Percentage of subjects with no disease progression at 6 months post-treatment [ Time Frame: 6 months after the End of Treatment (EOT) ]
    The End of Treatment (EOT) visit is performed within 30 days after a subject discontinues from study drug administration and prior to the subject beginning any subsequent anti-cancer therapy.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria:

  • Measurable disease per RECIST v1.1.
  • Life expectancy greater than or equal to 12 weeks.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • Adequate cardiovascular, hematological, liver, and renal function.
  • Histologically or cytologically confirmed diagnosis of advanced and/or metastatic solid tumors with at least one tumor lesion with location accessible to safely biopsy per clinical judgment of the Investigator. (Caution: Cohort D only patients with KRAS mutant colon cancer have not typically benefitted from the addition of cetuximab in earlier lines of therapy)
  • Prior anti-cancer therapy is allowed as long as any treatment related toxicity is resolved to an appropriate level.
  • Females of childbearing potential and men who are not surgically sterile must agree to use medically-accepted method of birth control during the study and for at least 3 months after last dose of treatment.
  • [Females] Negative serum pregnancy test within 7 days prior to initiating study treatment in premenopausal women and women less than 12 months after menopause.
  • [Males] Agreement to refrain from donating or banking sperm during the treatment period and for at least 3 months after last dose of study treatment.

Key Exclusion Criteria:

  • Radiotherapy ≤ 14 days prior to first dose of study drug (palliative radiation or stereotactic radiosurgery within 7 days prior to start of study treatment).
  • Treated with systemic anti-cancer therapy or an investigational agent within 2 weeks prior to start of study drug treatment (within 4 weeks for immunotherapy and tyrosine kinase inhibitor therapy).
  • Major surgery ≤ 30 days prior to first dose of study drug, or has not recovered to at least Grade 1 from adverse effects from such procedure, or anticipation of the need for major surgery during study treatment.
  • Active autoimmune disease requiring systemic treatment within the past 3 months or have a documented history of clinically severe autoimmune disease that requires systemic steroids or immunosuppressive agents.
  • Primary central nervous system (CNS) disease or leptomeningeal disease; known CNS metastases unless treated, are asymptomatic, are without evidence of radiological progression for at least 8 weeks, and have had no requirement for steroids or enzyme inducing anticonvulsants in the last 14 days prior to Screening.
  • Abnormal pulmonary function within the previous 6 months, including pneumonitis, active pneumonitis, interstitial lung disease requiring the use of steroids, idiopathic pulmonary fibrosis, confirmed pleural effusion, severe dyspnea at rest or requiring supplementary oxygen therapy.
  • Parenteral antibiotics within 14 days of the first dose of study drug.
  • History of allogenic or solid organ transplant.
  • Known human immunodeficiency virus (HIV) infection or active infection with hepatitis C.
  • Known uncontrolled hepatitis B virus (HBV) infection:

    • Anti-HBV therapy started before initiation of IMP and HBV viral load <2000 IU/mL (104 copies/mL) are eligible. The anti-HBV therapy should continue throughout the treatment period
    • Positive anti-HBc, positive anti HBs, negative HBsAg, and HBV virus load without HBV therapy are eligible
  • Clinically significant bleeding within 2 weeks prior to initial THOR-707 dose (e.g., gastrointestinal bleeding, intracranial hemorrhage).
  • Prior diagnosis of deep vein thrombosis or pulmonary embolism within 3 months.
  • Severe or unstable cardiac condition within 6 months prior to starting study treatment, such as congestive heart failure (New York Heart Association Class III or IV), cardiac bypass surgery or coronary artery stent placement, angioplasty, cardiac ejection fraction below the lower limit of normal, unstable angina, medically uncontrolled hypertension (e.g. ≥160 mm Hg systolic or ≥100 mm Hg diastolic), uncontrolled cardiac arrhythmia requiring medication (≥ grade 2, according to NCI CTCAE v5.0), or myocardial infarction.
  • History of non-pharmacologically induced prolonged corrected QT interval determined using Fridericia's formula (QTcF) > 450 milliseconds (msec) in males or > 470 msec in females.
  • Known hypersensitivity or contraindications to THOR-707, PEG, pegylated drugs, checkpoint inhibitor, or anti-EGFR antibody for applicable cohorts.
  • Active second malignancy, or history of previous malignancy that would impact the assessment of any study endpoints. Subjects with non-melanomatous skin cancer or cervical cancer that has been curatively surgically resected are eligible.
  • Any serious medical condition (including pre-existing autoimmune disease or inflammatory disorder), laboratory abnormality, psychiatric condition, or any other significant or unstable concurrent medical illness that in the opinion of the Investigator would preclude protocol therapy or would make the subject inappropriate for the study.
  • Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through 3 months after the last dose of study treatment.
  • Concurrent therapy with any other investigational agent, vaccine, or device. Concomitant participation in observational studies is acceptable after Sponsor approval.
  • For Cohort D only: patients with symptomatic keratitis and/or symptomatic dry eye should be excluded from enrollment. Patients who wear contact lenses should be advised to avoid contact lenses use as it could result in keratitis.
  • Subjects with baseline oxygen saturation <92% are not eligible for enrollment.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04009681


Contacts
Layout table for location contacts
Contact: Trial Transparency email recommended Toll Free Number for US and Canada 800-633-1610 ext option 6 Contact-US@sanofi.com

Locations
Layout table for location information
United States, Arizona
Investigational Site Number-1008 Recruiting
Scottsdale, Arizona, United States, 85250
United States, Colorado
Investigational Site Number-1005 Recruiting
Denver, Colorado, United States, 80218
United States, Florida
Investigational Site Number-1004 Recruiting
Sarasota, Florida, United States, 34232
United States, Tennessee
Investigational Site Number-1003 Recruiting
Nashville, Tennessee, United States, 37203
United States, Texas
Investigational Site Number-1007 Recruiting
Dallas, Texas, United States, 75032
Investigational Site Number-1002 Recruiting
Houston, Texas, United States, 77030
Investigational Site Number-1001 Recruiting
San Antonio, Texas, United States, 78229
Australia
Investigational Site Number-2004 Recruiting
New South Whales, Australia
Investigational Site Number-2001 Recruiting
Perth, Australia
Investigational Site Number-2002 Recruiting
Victoria, Australia
Investigational Site Number-2003 Recruiting
Victoria, Australia
Singapore
Investigational Site Number-4002 Recruiting
Singapore, Singapore
Investigational Site-4001 Recruiting
Singapore, Singapore
Sponsors and Collaborators
Synthorx, Inc, a Sanofi company
Investigators
Layout table for investigator information
Study Director: Clinical Sciences & Operations Sanofi
Layout table for additonal information
Responsible Party: Synthorx, Inc, a Sanofi company
ClinicalTrials.gov Identifier: NCT04009681    
Other Study ID Numbers: THOR-707-101 (TCD16843)
First Posted: July 5, 2019    Key Record Dates
Last Update Posted: July 11, 2022
Last Verified: July 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Synthorx, Inc, a Sanofi company:
Synthorx
THOR-707
THOR 707
Interleukin 2
Interleukin-2
IL2
oncology
immuno-oncology
immunotherapy
IL-2
SAR444245
Sanofi
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasm Metastasis
Neoplastic Processes
Neoplasms
Pathologic Processes
Antibodies
Immunologic Factors
Physiological Effects of Drugs